AstraZeneca: IMFINZI (Durvalumab) Plus Chemotherapy More Than Doubled Pathologic Complete Response Rate in Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers Versus Chemotherapy Alone
October 21, 2023
October 21, 2023
WILMINGTON, Delaware, Oct. 21 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in . . .
Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in . . .